Vaccine for aggressive breast cancer shows promise in early trial
A new vaccine for triple-negative breast cancer (TNBC) is showing early signs of hope.
In a small Phase 1 trial with 35 women, about three out of four developed the immune response researchers were looking for.
The vaccine was safe at its highest dose, with only mild injection-site reactions and no serious side effects.
Who was involved and what's next?
The study included women at high risk of TNBC coming back, those with certain genetic mutations planning preventive surgery, and some who hadn't fully responded to other treatments.
When paired with the cancer drug pembrolizumab, the vaccine boosted specific immune cells without extra risks.
Everyone in the study will be followed for five years, and larger trials are planned to start as soon as late 2026—so more answers could be on the way.